NKGN Key Statistics, Chart & Performance
The current stock price of NKGN is 0.1913 USD. In the past month the price decreased by -59.77%. In the past year, price decreased by -91.22%.
NKGN Latest News, Press Relases and Analysis
NKGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.92B | ||
| AMGN | AMGEN INC | 15.79 | 186.00B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 76.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 928.02 | 62.53B | ||
| INSM | INSMED INC | N/A | 44.10B | ||
| NTRA | NATERA INC | N/A | 32.88B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 20.71B | ||
| INCY | INCYTE CORP | 15.81 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About NKGN
Company Profile
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. The company is headquartered in Santa Ana, California and currently employs 63 full-time employees. The company went IPO on 2021-05-21. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. The company is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. The company is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Company Info
NKGEN BIOTECH INC
3001 Daimler St,
Santa Ana CALIFORNIA US
Employees: 63
Phone: 19493966830
NKGEN BIOTECH INC / NKGN FAQ
What does NKGN do?
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. The company is headquartered in Santa Ana, California and currently employs 63 full-time employees. The company went IPO on 2021-05-21. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. The company is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. The company is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Can you provide the latest stock price for NKGEN BIOTECH INC?
The current stock price of NKGN is 0.1913 USD. The price decreased by -62.91% in the last trading session.
Does NKGN stock pay dividends?
NKGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of NKGN stock?
NKGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What sector and industry does NKGEN BIOTECH INC belong to?
NKGEN BIOTECH INC (NKGN) operates in the Health Care sector and the Biotechnology industry.
Is NKGEN BIOTECH INC (NKGN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NKGN.
Can you provide the upcoming earnings date for NKGEN BIOTECH INC?
NKGEN BIOTECH INC (NKGN) will report earnings on 2025-04-14.
NKGN Technical Analysis
NKGN Financial Highlights
Over the last trailing twelve months NKGN reported a non-GAAP Earnings per Share(EPS) of -4.71. The EPS decreased by -50.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -564.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |